Clinical-stage biopharmaceutical company developing Nanobody-based immunotherapies for serious inflammatory diseases
Clinical-stage biopharmaceutical company developing Nanobody-based immunotherapies for serious inflammatory diseases. Its lead investigational medicine, sonelokimab, inhibits IL-17A and IL-17F and is being developed for inflammatory skin and joint diseases, including hidradenitis suppurativa, psoriasis, psoriatic arthritis, palmoplantar pustulosis, and ankylosing spondylitis.